Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Prospective Cohort Study to Evaluate the Safety and Effectiveness of Remsima® in the Treatment of Inflammatory Bowel Disease Among Saudi Arabia Patients Diagnosed With Crohn's Disease, Ulcerative Colitis, or Fistulizing CD

NCT03452501 is registered in ClinicalTrials.gov with Hikma Pharmaceuticals LLC as lead sponsor.

NCT NCT03452501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03452501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Prospective Cohort Study to Evaluate the Safety and Effectiveness of Remsima® in the Treatment of Inflammatory Bowel Disease Among Saudi Arabia Patients Diagnosed With Crohn's Disease, Ulcerative Colitis, or Fistulizing CD
Lead sponsor
Hikma Pharmaceuticals LLC
Phase
Observational
Overall status
Completed
Start date
August 26, 2018
Completion date
August 17, 2020
Enrollment
157 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, fistulizing crohn's disease, inflammatory bowel diseases, ulcerative colitis